Pasithea Therapeutics has selected a lead candidate for its PAS-003 program, which is intended to target a “velcro-like” protein to treat amyotrophic lateral sclerosis (ALS). The new therapy is a humanized monoclonal antibody that potently inhibits the alpha-5/beta-1 integrin protein. It was selected after extensive screening and characterization studies…
Two Canadian provinces — Prince Edward Island, and Newfoundland and Labrador — are covering the cost of the oral formulation of Radicava (edaravone) for eligible residents with amyotrophic lateral sclerosis (ALS). Patients will have access through their provincial drug plans to Radicava Oral Suspension, developed along with…
A particular genetic variant that boosts the activity of the NEAT1 gene can push the onset of amyotrophic lateral sclerosis (ALS) forward by more than three years, according to data from a large patient group in China. While the exact function of NEAT1 in ALS needs to be explored,…
A new advance in technology may pave the way for devices that could allow people with amyotrophic lateral sclerosis (ALS) who have lost the ability to speak to communicate using their thoughts alone. The new tech was described in a study, “High-resolution neural recordings improve the…
Having higher blood levels of uric acid may prevent or delay the decline in cognitive function in people with amyotrophic lateral sclerosis (ALS), according to a new study from Italy. High levels of uric acid are also associated with reduced odds of frontotemporal dementia, a form of dementia especially…
NeuroSense Therapeutics is planning to soon announce top-line safety and efficacy results from its PARADIGM trial, which is testing PrimeC in people with amyotrophic lateral sclerosis (ALS). News of trial findings being expected in December follows the dosing of a final patient in the randomized portion of…
The biotechnology company ProJenX recently received $15 million in funding to advance its experimental oral treatment prosetin for amyotrophic lateral sclerosis (ALS). This Series A financing round is essentially the next round of funding after seed money was used to rapidly develop the investigational treatment. Both rounds…
A person’s degree of exposure to multiple environmental pollutants — reflected by their presence in the blood — may be used to predict amyotrophic lateral sclerosis (ALS) risk and survival, according to new research. Greater exposure to these chemicals was associated with increased odds of an individual developing ALS,…
The genetic activity of certain brain cells, namely excitatory neurons and astrocytes, is altered in people with amyotrophic lateral sclerosis (ALS) caused by mutations in the C9ORF72 gene, a study reports. The data reveal the distinct molecular mechanisms that may lead to disease progression in people with such mutations, which…
Is it feasible to remotely collect health data from people with amyotrophic lateral sclerosis (ALS)? And would doing so help in gauging disease progression among patients? That’s what a remote observational study called ALS Go-Digital is now trying to assess. If validated, the approach could pave the way to…
